Merrill Lowers Sepracor Rating

Analyst Gregory Gilberts says the FDA's non-approval of Soltara was a very negative for the company

Shares of Sepracor (SEPR ) plunged after the U.S. Food and Drug Administration issued a non-approvable for the company's Soltara compound. Merrill Lynch downgraded the stock to near term reduce/sell from near term buy, and long term neutral from long term buy.

Analyst Gregory Gilberts says the FDA move was a very negative for Sepracor. In terms of financials, Gilberts removed Soltara revenues from his model, and slowed down expense growth as well. He had forecast revenues of $85 million form Soltara in 2002, rising to $600 million in 2005. The net effect: Gilberts narrowed his $5.22 2002 loss per share estimate to a $4.32 loss on the spending slowdown, but widened his $2.31 2003 loss estimate to a $4.62 loss. Once the stock corrects, says Gilberts, he will be in a better position to assess its potential. He points out that Sepracor's Xopenex franchise, and the company's product pipeline, have significant value.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE